OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter
HONG KONG, May 08, 2023 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, announced today that the high-pressure three-wire scoring balloon dilatation catheter Scoreflex TRIO developed and manufactured by its wholly-owned subsidiary OrbusNeich Medical (Shenzhen) Company Limited, has been used successfully in a PCI procedure for a 65-year-old patient with severe coronary artery stenosis and calcification. This first case of success marks the beginning of the clinical study across China for obtaining the product approval.
The principal investigator of the clinical study is the team led by Prof. Ge Junbo, Academician Zhongshan Hospital, Fudan University. Following the successful procedure on the first patient, the team highly commended the product, recognizing its ability to provide patients with a safe and effective treatment option.
Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, "OrbusNeich has launched earlier Scoreflex and Scoreflex NC scoring balloons in Mainland China, which are respectively the first scoring balloon and first high-pressure scoring balloon approved by the National Medical Products Administration. The clinical study on Scoreflex TRIO has officially begun now in Mainland China with the first successful trial recorded. The Group will continue to strive to provide more treatment options to patients in Mainland China. Scoreflex TRIO works in a way that can minimize damage to the interior of the arteries, making relevant procedures safer and more likely to succeed. Launched in Japan in 2021, it saw the Group achieving considerable growth in sales in Japan in 2022, while providing an effective and safe medical solution to many patients. The clinical study team led by famed Academician Ge Junbo has profound professional knowledge and clinical experience, hence we are confident of speeding up the study. In the past two decades, OrbusNeich has the service of very strong R&D and manufacturing teams and has also worked closely with clinical personnel to develop and launch interventional devices for PCI and PTA procedures to meet market demand. In the future, building on this solid foundation, the Group will strive to provide a variety of endovascular and structural heart interventional products to effectively improve the patients' quality of life."
About Scoreflex TRIO Scoreflex TRIO is the first China-made proprietary coronary three-wire scoring balloon dilatation catheter, developed by OrbusNeich Medical (Shenzhen) Company Limited. The product, through the radial or femoral arteries, channels the guidewires to the target lesions of the coronary arteries. The guidewire and the two integral wires on the balloon act as the external scoring elements, which can generate focal forces on the luminal surface of the balloon, allowing the balloon to open up the coronary lesions and dilate the narrowed coronary arteries at lower pressure, thus effectively stretch the diseased parts and prevent obvious intimal tear and dissection, thereby help improve blood flow and myocardial perfusion. Serving as the pre-dilatation balloon catheter in PCI, Scoreflex TRIO's longitudinal focused force angioplasty [FFA] mechanism can further reduce residual stenosis and improve procedural success relative to ordinary balloon dilation. It can also lower the chances of vascular intimal tear, reduce vascular damage and inflammation, enhancing procedural safety and reducing recurrence of stenosis. FFA mechanism of action of the high-pressure three-wire scoring balloon dilatation catheter allows vessel dilation at lower balloon pressure, such longitudinal progressive angioplasty can minimize vascular intimal damage, increase minimum lumen diameter and reduce residual stenosis.
About OrbusNeich Medical Group Holdings Limited OrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells products to over 70 countries and regions worldwide, and it is also the only PCI balloon manufacturer headquartered in China that ranked among the top 6 players in all major overseas PCI balloon markets including Japan (Ranked No. 2), Europe (Ranked No. 4), and the U.S. (Ranked No. 6) in terms of sales volume of PCI balloons in 2021 in accordance with the CIC Report. In addition, in terms of sales volume of PTA balloons in 2021, it ranked No. 3 in Japan and No. 4 in the U.S., respectively. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease areas. OrbusNeich owns more than 180 granted patents globally. Its in-house R&D team has over twenty years of product development experience and has developed proprietary, world leading technologies.
For more details, please visit the Group's official website: https://orbusneich.com/
Source: OrbusNeich Medical Group Holdings Limited Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Mitsubishi Power to Supply Technology to Support Brazil's Largest Reliability Project May 31, 2024 17:09 JST
| Team HRC Participation in the Suzuka 8 Hours Endurance Road Race 45th Tournament May 31, 2024 14:59 JST
| DOCOMO Launches Japan's First Demonstration Experiment of Self-powered Hydropower Base Station May 30, 2024 14:30 JST
| Fujitsu leverages data and AI to enable Panasonic EW's resilient supply chain management May 29, 2024 15:27 JST
| Hydrogen Engine Generator Set Ready for In-house Evaluation May 29, 2024 13:53 JST
| Hitachi and Google Cloud Announce Strategic Partnership to Accelerate Innovation and Productivity with Generative AI May 29, 2024 12:38 JST
| Japanese Consortium Achieves World's First Demonstration of 5G Communication from Altitude of 4km Using 38GHz Band May 29, 2024 11:44 JST
| Hitachi High-Tech Launches the SU3900SE and SU3800SE Series High-Resolution Schottky Field Emission Scanning Electron Microscopes Allowing Observation of Large and Heavy Samples at the Nano Level May 29, 2024 11:30 JST
| Celonis and NEC begin Proof of Concept Integrating Generative AI and Process Intelligence May 28, 2024 20:20 JST
| LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea May 28, 2024 15:19 JST
| Roche and Hitachi High-Tech extend their long-standing partnership May 28, 2024 12:53 JST
| Subaru, Toyota, and Mazda Commit to New Engine Development for the Electrification Era, Toward Carbon Neutrality May 28, 2024 12:45 JST
| Fujitsu unveils 1FINITY T250, an optical transmission solution that enables new connectivity services to achieve IOWN initiative May 28, 2024 10:45 JST
| Idemitsu Kosan, ENEOS, Toyota, and MHI Commence Study toward Introduction and Spread of Carbon-Neutral Fuels for Automobiles May 27, 2024 13:35 JST
| Toyota: Evolved Liquid Hydrogen-Powered GR Corolla to Participate in Super Taikyu Fuji 24 Hours Race May 24, 2024 16:19 JST
| Hitachi Energy's HVDC technology to power Marinus Link, a key step toward Australia's Net Zero ambitions May 24, 2024 14:39 JST
| Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 May 23, 2024 18:07 JST
| MHI Thermal Systems Receives JSRAE Technology Award for "e-3D Scroll" Compressor May 23, 2024 16:01 JST
| NEC X Invests in Agtech Startup Verdi, Integrates AI-Powered Platform with NEC's Cropscope Smart Farming Initiative May 23, 2024 11:20 JST
| 'Fujitsu Technology and Service Vision 2024': Leveraging AI and leading-edge technologies to deliver greater value to the environment, economies and people's well-being May 23, 2024 10:18 JST
|
More Latest Release >>
|